A sero-epidemiological study after two waves of the COVID-19 epidemic

The COVID-19 situation in Maldives have evolved since the epidemic began in March 2020 with unprecedented increase in cases since mid-July 2019 with over 8000 cases at the end of August 2020. The aim of the sero-epidemiological investigation is to obtain a sense of the population exposure to the SAR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Asian Pacific journal of allergy and immunology 2024-09, Vol.42 (3), p.270
Hauptverfasser: Abdul-Raheem, Raheema, Moosa, Sheena, Waheed, Fazeela, Aboobakuru, Maimoona, Ahmed, Ibrahim N, Rafeeg, Fathmath N, Saeed, Mariya
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page 270
container_title Asian Pacific journal of allergy and immunology
container_volume 42
creator Abdul-Raheem, Raheema
Moosa, Sheena
Waheed, Fazeela
Aboobakuru, Maimoona
Ahmed, Ibrahim N
Rafeeg, Fathmath N
Saeed, Mariya
description The COVID-19 situation in Maldives have evolved since the epidemic began in March 2020 with unprecedented increase in cases since mid-July 2019 with over 8000 cases at the end of August 2020. The aim of the sero-epidemiological investigation is to obtain a sense of the population exposure to the SARS-CoV-2 by measuring the seroprevalence of antibodies to COVID-19 in the general population. A population-based, age-stratified prospective method was employed to find out the key epidemiological and serologic characteristics of COVID-19 virus in this study. The results showed that seroprevalence in the population was 13%. The factors that were associated with antibody results included age (OR: 4.0, CI: 1.7-9.0), nationality (OR: 12.9, CI: 8.3-19.7), being diagnosed for COVID-19 (OR: 24.7, CI: 15.9-38.4) and having symptoms of COVID-19 (OR: 2.0, CI: 1.5-2.8). There was a gradual decrease in the antibody levels from 19 days to 250 days. The mean duration of the presence of antibodies in this study was found to be 124 days. While the seroprevalence provides a measure that can be used to predict community transmission risk of the disease, the extent of functional immunity provided by antibody titres is still not clear. It is acknowledged that other mechanisms of protection such as T cell mediated immunity will play an important role in providing individual protection.
doi_str_mv 10.12932/ap-040721-1177
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2614755389</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2614755389</sourcerecordid><originalsourceid>FETCH-LOGICAL-c222t-c18601ee8557a3cc4bba3757b9104b3f1cd024ba459cd2bda623b47f6e8720123</originalsourceid><addsrcrecordid>eNo9kD1PwzAQhi0EolXpzIY8spj6_BE7Y1UKVEIqAyA2y3YcCEpwiROq_nsCLdxyy_O-unsQOgd6BSznbGY3hAqqGBAApY7QmDGmic5ycYzGFJgkWqmXEZqm9E6HyQC0FKdoxEUuuVBijJZznEIbSdhURWiqWMfXytsap64vdtiWXWhxt414a79CwrHE3VvAi_Xz6ppAjg8pf4ZOSlunMD3sCXq6WT4u7sj9-na1mN8TP1zWEQ86oxCCllJZ7r1wznIllcuBCsdL8AVlwlkhc18wV9iMcSdUmQWt2PAPn6DLfe-mjZ99SJ1pquRDXduPEPtkWAZCScl1PqCzPerbmFIbSrNpq8a2OwPU_Ooz8wez12d-9A2Ji0N575pQ_PN_svg3WDFopA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2614755389</pqid></control><display><type>article</type><title>A sero-epidemiological study after two waves of the COVID-19 epidemic</title><source>Free E-Journal (出版社公開部分のみ)</source><source>Alma/SFX Local Collection</source><creator>Abdul-Raheem, Raheema ; Moosa, Sheena ; Waheed, Fazeela ; Aboobakuru, Maimoona ; Ahmed, Ibrahim N ; Rafeeg, Fathmath N ; Saeed, Mariya</creator><creatorcontrib>Abdul-Raheem, Raheema ; Moosa, Sheena ; Waheed, Fazeela ; Aboobakuru, Maimoona ; Ahmed, Ibrahim N ; Rafeeg, Fathmath N ; Saeed, Mariya</creatorcontrib><description>The COVID-19 situation in Maldives have evolved since the epidemic began in March 2020 with unprecedented increase in cases since mid-July 2019 with over 8000 cases at the end of August 2020. The aim of the sero-epidemiological investigation is to obtain a sense of the population exposure to the SARS-CoV-2 by measuring the seroprevalence of antibodies to COVID-19 in the general population. A population-based, age-stratified prospective method was employed to find out the key epidemiological and serologic characteristics of COVID-19 virus in this study. The results showed that seroprevalence in the population was 13%. The factors that were associated with antibody results included age (OR: 4.0, CI: 1.7-9.0), nationality (OR: 12.9, CI: 8.3-19.7), being diagnosed for COVID-19 (OR: 24.7, CI: 15.9-38.4) and having symptoms of COVID-19 (OR: 2.0, CI: 1.5-2.8). There was a gradual decrease in the antibody levels from 19 days to 250 days. The mean duration of the presence of antibodies in this study was found to be 124 days. While the seroprevalence provides a measure that can be used to predict community transmission risk of the disease, the extent of functional immunity provided by antibody titres is still not clear. It is acknowledged that other mechanisms of protection such as T cell mediated immunity will play an important role in providing individual protection.</description><identifier>ISSN: 0125-877X</identifier><identifier>EISSN: 2228-8694</identifier><identifier>DOI: 10.12932/ap-040721-1177</identifier><identifier>PMID: 34953474</identifier><language>eng</language><publisher>Thailand</publisher><ispartof>Asian Pacific journal of allergy and immunology, 2024-09, Vol.42 (3), p.270</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34953474$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Abdul-Raheem, Raheema</creatorcontrib><creatorcontrib>Moosa, Sheena</creatorcontrib><creatorcontrib>Waheed, Fazeela</creatorcontrib><creatorcontrib>Aboobakuru, Maimoona</creatorcontrib><creatorcontrib>Ahmed, Ibrahim N</creatorcontrib><creatorcontrib>Rafeeg, Fathmath N</creatorcontrib><creatorcontrib>Saeed, Mariya</creatorcontrib><title>A sero-epidemiological study after two waves of the COVID-19 epidemic</title><title>Asian Pacific journal of allergy and immunology</title><addtitle>Asian Pac J Allergy Immunol</addtitle><description>The COVID-19 situation in Maldives have evolved since the epidemic began in March 2020 with unprecedented increase in cases since mid-July 2019 with over 8000 cases at the end of August 2020. The aim of the sero-epidemiological investigation is to obtain a sense of the population exposure to the SARS-CoV-2 by measuring the seroprevalence of antibodies to COVID-19 in the general population. A population-based, age-stratified prospective method was employed to find out the key epidemiological and serologic characteristics of COVID-19 virus in this study. The results showed that seroprevalence in the population was 13%. The factors that were associated with antibody results included age (OR: 4.0, CI: 1.7-9.0), nationality (OR: 12.9, CI: 8.3-19.7), being diagnosed for COVID-19 (OR: 24.7, CI: 15.9-38.4) and having symptoms of COVID-19 (OR: 2.0, CI: 1.5-2.8). There was a gradual decrease in the antibody levels from 19 days to 250 days. The mean duration of the presence of antibodies in this study was found to be 124 days. While the seroprevalence provides a measure that can be used to predict community transmission risk of the disease, the extent of functional immunity provided by antibody titres is still not clear. It is acknowledged that other mechanisms of protection such as T cell mediated immunity will play an important role in providing individual protection.</description><issn>0125-877X</issn><issn>2228-8694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNo9kD1PwzAQhi0EolXpzIY8spj6_BE7Y1UKVEIqAyA2y3YcCEpwiROq_nsCLdxyy_O-unsQOgd6BSznbGY3hAqqGBAApY7QmDGmic5ycYzGFJgkWqmXEZqm9E6HyQC0FKdoxEUuuVBijJZznEIbSdhURWiqWMfXytsap64vdtiWXWhxt414a79CwrHE3VvAi_Xz6ppAjg8pf4ZOSlunMD3sCXq6WT4u7sj9-na1mN8TP1zWEQ86oxCCllJZ7r1wznIllcuBCsdL8AVlwlkhc18wV9iMcSdUmQWt2PAPn6DLfe-mjZ99SJ1pquRDXduPEPtkWAZCScl1PqCzPerbmFIbSrNpq8a2OwPU_Ooz8wez12d-9A2Ji0N575pQ_PN_svg3WDFopA</recordid><startdate>20240901</startdate><enddate>20240901</enddate><creator>Abdul-Raheem, Raheema</creator><creator>Moosa, Sheena</creator><creator>Waheed, Fazeela</creator><creator>Aboobakuru, Maimoona</creator><creator>Ahmed, Ibrahim N</creator><creator>Rafeeg, Fathmath N</creator><creator>Saeed, Mariya</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240901</creationdate><title>A sero-epidemiological study after two waves of the COVID-19 epidemic</title><author>Abdul-Raheem, Raheema ; Moosa, Sheena ; Waheed, Fazeela ; Aboobakuru, Maimoona ; Ahmed, Ibrahim N ; Rafeeg, Fathmath N ; Saeed, Mariya</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c222t-c18601ee8557a3cc4bba3757b9104b3f1cd024ba459cd2bda623b47f6e8720123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abdul-Raheem, Raheema</creatorcontrib><creatorcontrib>Moosa, Sheena</creatorcontrib><creatorcontrib>Waheed, Fazeela</creatorcontrib><creatorcontrib>Aboobakuru, Maimoona</creatorcontrib><creatorcontrib>Ahmed, Ibrahim N</creatorcontrib><creatorcontrib>Rafeeg, Fathmath N</creatorcontrib><creatorcontrib>Saeed, Mariya</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Asian Pacific journal of allergy and immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abdul-Raheem, Raheema</au><au>Moosa, Sheena</au><au>Waheed, Fazeela</au><au>Aboobakuru, Maimoona</au><au>Ahmed, Ibrahim N</au><au>Rafeeg, Fathmath N</au><au>Saeed, Mariya</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A sero-epidemiological study after two waves of the COVID-19 epidemic</atitle><jtitle>Asian Pacific journal of allergy and immunology</jtitle><addtitle>Asian Pac J Allergy Immunol</addtitle><date>2024-09-01</date><risdate>2024</risdate><volume>42</volume><issue>3</issue><spage>270</spage><pages>270-</pages><issn>0125-877X</issn><eissn>2228-8694</eissn><abstract>The COVID-19 situation in Maldives have evolved since the epidemic began in March 2020 with unprecedented increase in cases since mid-July 2019 with over 8000 cases at the end of August 2020. The aim of the sero-epidemiological investigation is to obtain a sense of the population exposure to the SARS-CoV-2 by measuring the seroprevalence of antibodies to COVID-19 in the general population. A population-based, age-stratified prospective method was employed to find out the key epidemiological and serologic characteristics of COVID-19 virus in this study. The results showed that seroprevalence in the population was 13%. The factors that were associated with antibody results included age (OR: 4.0, CI: 1.7-9.0), nationality (OR: 12.9, CI: 8.3-19.7), being diagnosed for COVID-19 (OR: 24.7, CI: 15.9-38.4) and having symptoms of COVID-19 (OR: 2.0, CI: 1.5-2.8). There was a gradual decrease in the antibody levels from 19 days to 250 days. The mean duration of the presence of antibodies in this study was found to be 124 days. While the seroprevalence provides a measure that can be used to predict community transmission risk of the disease, the extent of functional immunity provided by antibody titres is still not clear. It is acknowledged that other mechanisms of protection such as T cell mediated immunity will play an important role in providing individual protection.</abstract><cop>Thailand</cop><pmid>34953474</pmid><doi>10.12932/ap-040721-1177</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0125-877X
ispartof Asian Pacific journal of allergy and immunology, 2024-09, Vol.42 (3), p.270
issn 0125-877X
2228-8694
language eng
recordid cdi_proquest_miscellaneous_2614755389
source Free E-Journal (出版社公開部分のみ); Alma/SFX Local Collection
title A sero-epidemiological study after two waves of the COVID-19 epidemic
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A36%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20sero-epidemiological%20study%20after%20two%20waves%20of%20the%20COVID-19%20epidemic&rft.jtitle=Asian%20Pacific%20journal%20of%20allergy%20and%20immunology&rft.au=Abdul-Raheem,%20Raheema&rft.date=2024-09-01&rft.volume=42&rft.issue=3&rft.spage=270&rft.pages=270-&rft.issn=0125-877X&rft.eissn=2228-8694&rft_id=info:doi/10.12932/ap-040721-1177&rft_dat=%3Cproquest_cross%3E2614755389%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2614755389&rft_id=info:pmid/34953474&rfr_iscdi=true